The selective pressures leading to cancers with mutations in both KRAS and PIK3CA are unclear.
RAS can contribute to tumorigenesis in human epithelial cells (2) , overexpression of mutant RAS also has been shown to result in oncogene induced senescence in human fibroblasts (3) .
Additionally, recent studies have demonstrated that tissue specific expression of other tumor suppressors can also influence the carcinogenic potential of mutant KRAS (4).
It is also uncertain as to why mutations in RAS genes and PIK3CA, the gene encoding the p110α subunit of PI3 Kinase α, are found concurrently in human cancers since both mutations result in increased signaling through the MAP Kinase and PI3 Kinase pathways (5) (6) (7) . Specific selective pressures may allow for the emergence of such double mutant tumors and indeed, recent studies suggest that the presence or absence of mutant KRAS with mutant PIK3CA can alter drug resistance and sensitivity to various inhibitors in the MAP Kinase and PI3 Kinase pathways (8, 9) . More recent studies propose that activation of the PI3 Kinase pathway may be dominant and override senescence that can be seen with overexpression of mutant Ras thus conferring a growth advantage for double mutant cancer cells (10) . Author Manuscript Published OnlineFirst on ; DOI: 10.1158/0008-5472. CAN-12-1578 G. Wang et al. 4 "knock in" of a single KRAS mutation in immortalized human breast epithelial cells and mouse liver cells did not result in any obvious phenotype (11, 12) . It is possible that the tissue specific and/or genetic context of these two different cell types precluded the ability for mutant KRAS to elicit any appreciable phenotype. However, arguing against this is the fact that overexpression of a transgene mutant KRAS cDNA in these cell lines led to expected transformed phenotypes.
These results could be explained by the fact that increased copy number/expression of mutant KRAS may be needed to impart a cancerous phenotype. Indeed, studies have reported that increased copy number of mutant KRAS is found in a significant fraction of human tumors (13) , suggesting that multiple copies of mutant KRAS may impart a stronger oncogenic signal than a single mutant KRAS allele. Seemingly in contrast to this latter finding, sophisticated mouse tumor models incorporating single latent and/or conditional alleles of mutant KRAS have been developed, but interestingly the tumors that arise from these mice often have increased copy numbers of mutant KRAS (14) , again implying that a single copy of mutant KRAS can predispose to, but is not sufficient for tumor formation.
In contrast to the somatic cell knock in models, elegant work in colorectal cancer cell lines has demonstrated that selective single allele "knock out" of mutant versus wild type KRAS leads to dramatic effects including decreased tumorigenicity and other features of transformation in vitro (15, 16) . However, the DLD1 and HCT-116 cell lines used in these studies also harbor other mutations including single allelic oncogenic PIK3CA mutations in exons 9 and 20, respectively (17) . Interestingly, these cell lines are derived from colorectal cancers with a microsatellite instability (MIN) phenotype, leading to a mostly diploid genome. We reasoned demonstrating that increased copy number of these mutant alleles is not necessary for tumorigenesis. Using human samples from colorectal cancer patients, similar results were seen using a combination of FISH probes and standard sequencing. Mechanistically, cooperativity seen with mutant KRAS and PIK3CA is dependent on Ras/p110α binding as evidenced by functional mutation analysis of the RBD in p110α. In addition, further studies using small molecule inhibitors demonstrate that Pdk1 activation with subsequent downstream phosphorylation of p90RSK is differentially regulated in cells containing both mutant KRAS and mutant PIK3CA compared to their single mutant knock in counterparts. These findings elucidate a new mechanism of how single mutant KRAS and PIK3CA alleles can cooperate to induce a transformed phenotype and explain why concurrent mutations may be selected for in certain cancers. 
Materials and Methods
Cell culture. The non-transformed human breast epithelial cell line MCF-10A (20) and its derivatives were grown in DMEM/F12 (1:1) supplemented with 5% horse serum (Hyclone), EGF at 20 ng/ml, insulin at 10 μg/ml, hydrocortisone at 0.5 μg/ml, and cholera toxin at 0.1 μg/ml (hereafter denoted as ''supplemented DMEM/F12''). Cell lines with gene targeted PIK3CA mutations were grown in supplemented DMEM/F12 media without EGF. Retroviral infected cells were grown in supplemented DMEM/F12 media with 120ng/ml G418. MDA-MB-231 cells, HCT-116 cells and their derivatives were grown in DMEM media with 5% fetal bovine serum. All supplements were purchased from Sigma-Aldrich unless otherwise noted. MCF-10A
and MDA-MB-231 cells were purchased from ATCC. HCT-116 derivatives were a generous gift from Dr. Bert Vogelstein.
Targeted knock in of oncogenic PIK3CA mutations and characterization of clones. Targeted knock in of PIK3CA exon 9 (E545K) and exon 20 (H1047R) mutations into MCF-10A cells already carrying a heterozygous KRAS G12V knock in mutation was conducted as previously described (6) . We isolated two independently derived knock in clones each for E545K and H1047R mutations, as well as one randomly integrated control clone for each targeting vector.
We also derived a "Targeted Wild Type" control for the E545K targeting vector whereby gene targeting had occurred at the correct locus, but the mutation in the homology arm was not retained, likely due to an early cross over event during homologous recombination as previously described (11) . The knock in clones were determined to be single targeted homologous integrants with equal expression of mutant and wild type PIK3CA through PCR and direct sequencing of gDNA and cDNA, respectively ( Figure S1 ). Single stranded cDNA was generated using First Primer sequences for PCR amplification and sequencing are shown in Table S6 .
Cell proliferation and drug inhibitor assays
For cell growth assays in EGF-free conditions, exponentially growing cells were washed with HBSS twice and seeded in DMEM/F12 medium without EGF, using 1% charcoal dextran-treated fetal bovine serum, using 1% charcoal dextran treated serum, insulin at 10 μg/ml, hydrocortisone at 0.5 μg/ml, and cholera toxin at 0.1 μg/ml, without EGF or with 0.2 ng/ml EGF as indicated, Cells were seeded at a density of 2x10 4 cells/well of a 6-well tissue culture dish on day 0.
Medium was changed every third day. Cells were harvested on days 1, 6, 11, and 16, and cell numbers were counted using a Beckman Coulter counter. In some assays, cells were also stained with crystal violet (Sigma) after 3 days, or when cells in control flasks were ~90-95% confluent, diluted in formalin at a concentration of 2 mg/ml. For drug inhibitor assays, U0126 and rapamycin were purchased from Cell Signaling (Danvers, MA). Compounds were dissolved in DMSO which was also used as a vehicle only control in drug assays and used at concentrations of 1uM for U0126 and 1nM for rapamycin. GSK2334470 was purchased from Sigma and used at 5uM after establishing dosing curves for the cell lines. Drugs were added to cells with media changes as described above for proliferation assays. All assays and growth conditions were performed in triplicate and repeated at least twice.
Colony formation assay in semisolid medium and acinar morphogenesis assay
For colony formation assays, 3x10 poured on top of a 2 ml bottom layer containing 0.6% agarose in 6-well tissue culture plates.
Supplemented DMEM/F12 was added to the wells once a week. After 3 weeks of incubation, the colonies were stained with MTT (2-(3,5-diphenyltetrazol-2-ium-2-yl)-4,5-dimethyl-1,3-thiazole bromide) and visually inspected for colonies. Photos were taken with a phase contrast microscope (Nikon). Morphogenesis assays were carried out as previously described (21) .
Photographs were taken under phase contrast microscopy after three weeks of incubation.
Immunoblotting
Cells were seeded in media using EGF-free conditions for proliferation assays. HCT-116 derivative cells were seeded in media using EGF-free DMEM media with 0.5% charcoal dextran-treated fetal bovine serum. Cells were harvested after 48 hours for protein lysates, and immunoblotting was performed as previously described (11) . In experiments with inhibitors, after 24 hours, the media was then changed so that cells were incubated for an additional 24 hours with or without drugs. Briefly, whole cell protein extracts prepared in Laemmli sample buffer were resolved by SDS-PAGE using NuPAGE gels (Invitrogen), transferred to Invitrolon PVDF membranes (Invitrogen), and probed with primary antibody followed by incubation with 
Immunohistochemistry
Immunohistochemical labeling of xenografts was performed on paraffin-embedded samples.
Briefly, 4 μm sections were deparaffinized in xylene for 30 minutes and rehydrated using graded 
Retrovirus
Two pLXSN PIK3CA vectors were created using RT-PCR to clone cDNA with an activating PIK3CA mutation (either E545K or H1047R, respectively) as well as two RBD mutations (T208D and K227A). Mutations were introduced using PCR site directed mutagenesis (22) .
Retroviral vector was produced using AmphoPack-293 cells (BD Clontech) according to the manufacturer's instructions and used for cell infection with 8 ng/mL of polybrene (SigmaAldrich). Antibiotic selection was started 3 days post infection and continued for 2 weeks before performing assays.
Quantitative real time PCR analyses
Cells were seeded at equal density and harvested the next day for gDNA using QIAamp DNA blood mini kits (Qiagen). Real time quantitative PCR was then performed as previously described (23) . Primers used for real time PCR are listed in Table S6 . 
Cell Cycle Analysis with Flow Cytometery
Cells were seeded in 6-well plates and were then harvested the next day. Cells were fixed in phosphate buffered saline/3% formaldehyde/0.4% NP-40 containing 2 µg/mL Hoechst 33258 (Invitrogen). DNA content was measured with a BD LSR flow cytometer (BD Biosciences), and percentages of G1/G0, S, and G2/M phase cells were determined using Modfit LT software (Verity Software House).
Statistical Analysis
All statistical analyses were performed using GraphPad InStat software (La Jolla, CA). A P value of less than 0.05 was considered significant.
RESULTS

Gene targeting to create mutant KRAS/PIK3CA knock in cell lines.
To address the hypothesis that mutant KRAS as a single copy may be oncogenic in the context of mutant PIK3CA, we performed gene targeting to separately knock in oncogenic PIK3CA mutations (E545K and H1047R) into MCF-10A cells already containing a KRAS G12V mutation that had been generated via somatic cell gene targeting (11) . MCF-10A is a spontaneously immortalized non-tumorigenic human mammary epithelial cell line that is genetically stable with a mostly diploid karyotype (20, 24) . Importantly, various models using transgene overexpression have demonstrated that MCF-10A cells can be transformed with mutant oncogene overexpression and selection in vivo as xenografts (25) . We employed two vectors as described (6) to knock in the oncogenic hotspot PIK3CA mutations E545K and H1047R located in exons 9 and 20 of the PIK3CA gene, respectively. Using a pooled screening strategy (26), multiple gene targeting events were identified and two double knock in (DKI) clones were generated with each mutant PIK3CA targeting vector. Determining the relative ratios using sequencing analysis confirmed a single gene targeted event as well as equal expression from both alleles ( Figure S1A ). We also generated a gene-targeted wild type control clone dubbed Targeted WT (KRAS G12V/PIK3CA E545E) wherein homologous recombination occurred without integration of the PIK3CA E545K mutation ( Figure S1 ). In addition, we isolated one non-gene targeted random integrant (RI) control for each vector. A complete list of the cell lines generated and used in this study can be found in Table S1 .
Mutant KRAS cooperates with mutant PIK3CA in vitro.
To characterize DKI cells for properties of transformation, we employed a number of different in vitro assays as previously described (6, 11, 27) . MCF-10A cells require epidermal growth factor (EGF) for continuous proliferation, and growth factor independence is often associated with a transformed phenotype. In previous studies, KRAS G12V knock in mutations did not yield appreciable growth factor independence in human mammary epithelial cell lines, while PIK3CA single knock in mutations, E545K and H1047R, conferred EGF independence (6, 11) . We found that in the absence of EGF, the DKI cells have increased proliferation rates compared to single G. Wang et al. 13 have no obvious phenotype and the two mutations together are therefore greater than the sum of the individual parts. Cell cycle analyses using flow cytometry was performed and demonstrated an increase in S phase in DKI cells compared with control and single mutant PIK3CA cell lines (Table S2) . We then cultured DKI clones and control cells in semi-solid medium in order to assess their capacity to form anchorage-independent colonies, another feature of transformation in vitro. In this assay, equal number of cells were plated, and DKI clones formed colonies that were relatively small and fewer in number compared to the positive control of mutant KRAS overexpressing cells (Table S3 ), but were clearly present relative to control and single knock in cell lines ( Figure 2 ). Subsequently we grew DKI clones in Matrigel, a three-dimensional basement membrane culture that supports acini formation of mammary epithelial cells in vitro (28) . KRAS and PIK3CA single knock in clones showed no structural difference from wild type MCF-10A cells as previously reported ( Figure S1B ). In contrast, DKI clones showed striking phenotypic changes, including protrusions at the borders of acini, bridging between neighboring acini, and loss of structural integrity. These features resemble the invasive process of cancers and can also be seen in single PIK3CA knock in clones supplemented with high doses of EGF as previously described (27) , suggesting that DKI cells may have increased activation of MAP Kinase and PI3 Kinase pathways.
DKI cells form tumors in immunocompromised mice and retain single copies of mutant KRAS and PIK3CA.
The ability to form tumors in immunocompromised mice is often a hallmark of in vivo transformation. We subsequently tested DKI clones in xenograft assays using athymic nude mice. Consistent with previous data, KRAS and PIK3CA single knock in clones were not capable Figure   S2D ). These data confirm that single mutant copies of both KRAS and PIK3CA are sufficient for initiating and maintaining tumorigenesis, whereas mutation of either KRAS or PIK3CA as single copies is not adequate for tumorigenesis but likely predisposes to tumor formation. dramatically affects tumorigenicity (8, 15, 16) . Although the original report by Shirasawa et al.
described a complete absence of tumor formation, our own unpublished observations and those of others demonstrated that knock out of mutant but not wild type KRAS results in a severely reduced tumorigenic phenotype, though tumor formation occurs in all inoculated mice (8, 15) .
More recently it has been described that DLD1 and HCT-116 also have oncogenic PIK3CA mutations in exons 9 and 20, respectively (17) . In contrast to mutant KRAS knock out cell lines, somatic cell knock out of either the mutant or wild type PIK3CA allele in these cell lines was reported as having no effect on tumorigenicity. However, these results were presented qualitatively as the presence or absence of tumors. In our experiments, knock out of mutant versus wild type PIK3CA in HCT-116 cells led to dramatic differences in tumor volume and longer latency ( Figure S3 ), though similar to the data by Samuels et al., all inoculated mice formed tumors. Taken together, these data suggest that in cancer cells containing a single allele of mutant KRAS and a single allele of mutant PIK3CA, both mutant oncogenes are necessary for conferring increased properties of cellular transformation.
DKI cells have increased phosphorylation of p90RSK and p70S6K.
To elucidate how mutant KRAS cooperates with mutant PIK3CA to impart a cooperative phenotype, we analyzed the MAP Kinase and PI3 Kinase pathways via western blot in DKI cells and control cell lines. It has been shown that endogenous knock in of single PIK3CA mutations activates both PI3 Kinase and MAP Kinase pathways, whereas mutant KRAS knock in alone has no effect on downstream molecules in either pathway (6, 11) . Using whole cell lysates prepared 
demonstrated increased p90RSK phosphorylation relative to single knock in cells and controls suggesting that the presence of mutant KRAS with mutant PIK3CA also increases activation of the MAP Kinase pathway. We also examined substrates of p70S6K and p90RSK that is, phosphorylation of S6 ribosomal protein and 4E-BP1. As shown in Figure S5 , phosphorylation of S6 was markedly increased in DKI cells relative to controls and single mutant PIK3CA knock in cells, whereas somewhat surprisingly, no increases in phosphorylation of 4E-BP1 were noted.
The reasons for this are unclear but may be due to altered "rewiring" of signaling pathways that can occur when oncogenes become mutated. To determine if these results were reproducible in other cell types, we obtained the HCT-116 mutant versus wild type KRAS knock out cell lines (32) and examined their p90RSK and p70S6K phosphorylation status. As seen in Figure 5B 
little effect under no EGF conditions for both single mutant PIK3CA knock in cells as previously reported (6) , and DKI cells ( Figure S6B ). In our prior work (6), lack of mTOR activation in no EGF conditions explained rapamycin resistance, yet mTOR activation is clearly present in DKI cells. Western blot analyses of DKI cells versus parental MCF-10A cells demonstrated that Mek inhibition with U0126 led to slight decreases in p70S6K phosphorylation, and minimal decrease to no change in p90RSK phosphorylation, however, rapamycin treatment had the predicted effect of dramatically reducing phosphorylation of p70S6K, but the unexpected finding of increased phosphorylation of p90RSK ( Figure S6C ). Although the mechanism of this is unknown, it is highly reminiscent of the known inhibition of the negative feedback loop that is seen with rapamycin leading to increased PI3 Kinase pathway activation as previously mentioned (30, 31) , and may represent an explanation of how combined mutant KRAS with mutant PIK3CA leads to resistance against mTOR inhibitors as described by Bardelli and colleagues (8) . To examine the effects of rapamycin on Akt phosphorylation on DKI cells, lysates with and without rapamycin were probed ( Figure S6D Figure S6D, bottom panel) . These results demonstrated a dramatic decrease in Erk phosphorylation with U0126 treatment, but no affect on Akt phosphorylation. Finally, to ensure the rapamycin resistance seen in DKI was not due to technical reasons, we then repeated the assays with physiologic EGF concentrations, as single mutant PIK3CA knock in clones are differentially inhibited with rapamycin under these conditions (6) . As shown in Figure S6E , single mutant PIK3CA clones were now sensitive to rapamycin, yet DKI cells retained a relatively resistant phenotype.
To further determine the effects of mutant KRAS and mutant PIK3CA on downstream signaling and growth, additional assays using treatment with both rapamycin and U0126 were performed. As seen in Figure S6F , dual inhibitor treatment produced a western blot pattern that was "predominated" by rapamycin's effects. That is, slight decreases and increases in Akt phosphorylation occurred in the DKI2, DKI3 and DKI5, DKI6 clones, respectively, along with dramatic decreases in p70S6K phosphorylation. Additionally, Erk phosphorylation was slightly increased in all DKI clones. These results mimicked single treatment with rapamycin in DKI cells. In contrast, phosphorylation of p90RSK appeared "even" in that the minimal decrease with U0126 as a single agent appeared offset by the increase seen with rapamycin alone, yielding a net result of no change. In accord with these results, dual treatment led to a relative resistance phenotype in DKI clones that was still sensitive relative to rapamycin alone, but more resistant than U0126 single treatment ( Figure S6G ). These results are intriguing in that they may point out potential caveats in treating mutant KRAS and mutant PIK3CA cancers for dual pathway inhibitor trials currently being initiated. Regardless, these data collectively demonstrate that Akt signaling is remains intact in DKI clones and that mTORC1 activity is responsible for p70S6K activation. However, given the minimal increases and decreases in p90RSK phosphorylation, we sought additional mechanisms as to how mutant KRAS cooperates with mutant PIK3CA to impart a transformed phenotype.
Increased phosphorylation of p90RSK and p70S6K in DKI cells is mediated in part by
Ras/p110α interaction and Pdk1 activity.
We next sought to determine how mutant KRAS cooperates with mutant PIK3CA. Previous work by others demonstrated that mutant Ras signals through the RBD of p110α (18) . Based upon these studies, we reasoned that the interaction of mutant Kras specifically with mutant p110α could lead to increased activation of downstream pathways. We tested this hypothesis by mutational analysis of the RBD within p110α. We initially created a gene targeting vector with missense mutations in the RBD (T208D, K227A) similar to prior studies (18) , and transduced these vectors into HCT-116 (H1047R) and DLD1 (E545K) colon cancer cell lines to obtain hemizygously targeted clones (data not shown). These missense mutations within the RBD have previously been reported to abrogate Ras/p110α binding while leaving other functions of p110α intact (18) . Upon analyzing the cDNA from these clones using RT-PCR, we discovered that in 8 of 8 HCT-116 and 7 of 7 DLD1 clones, the RBD targeting vector had incorporated into the wild type PIK3CA allele (p<0.0001 assuming equal allele targeting frequency) (Table S4 ). We then used the same vector to target DKI cells and but due to technical reasons, we did not generate sufficient G418 resistant colonies to screen and obtain gene targeted DKI/RBD clones. However at this juncture based upon our results with the HCT-116 and DLD1 cell lines, we decided to employ a different strategy. between mutant Kras and mutant p110α, though non-specific transgene effects using these vectors could not be ruled out. Regardless, the studies presented here further underscore the importance of Ras binding to p110α, as this interaction is necessary for full cooperativity between these two mutant oncoproteins leading to a cooperative effect. Interestingly, as mentioned previously some studies have shown differences in exon 9 (E542K, E545K) and exon 20 (H1047R) PIK3CA mutations in their requirement for Ras binding (34) , and our results with rapamycin on Akt phosphorylation ( Figure S6D ) support this notion. However, in contrast our results with these growth assays did not show appreciable differences between E545K and H1047R mutations in the context of RBD mutations. Unfortunately, the transient nature of this system prevented the ability to assess the effects of RBD mutations on longer term assays including Matrigel and xenograft tumorigenicity assays.
To further characterize the cooperativity seen with mutant KRAS and mutant PIK3CA, we performed additional western blot experiments using our retroviral system. Both MCF-10A and KRAS G12V knock in cells transduced with mutant PIK3CA cDNAs resulted in relatively equivalent increased levels of phosphorylated Akt, however cells infected with mutant PIK3CA cDNAs containing RBD mutations showed a relative decrease in phosphorylated Akt ( Figure   6C ). Given that oncogenic PIK3CA mutations are thought to constitutively active the PI3 Kinase enzyme, this result was somewhat unexpected but suggests that oncogenic PIK3CA mutations require Ras binding for PI3K activation, an observation that helps to explain our results with RBD gene targeting of the HCT-116 and DLD1 cancer cell lines. In addition, Erk phosphorylation was increased at relatively equal levels in both MCF-10A and KRAS G12V transgene expressing cells akin to PIK3CA single knock in and DKI clones. In striking contrast to Akt phosphorylation, RBD mutations appeared to have no effect on Erk phosphorylation. The (35) . Pdk1 is thought to be an important substrate of PI3 Kinase and directly phosphorylates specific residues of key downstream effectors such as Akt and p90RSK (36) . We had initially examined Pdk1 phosphorylation and found no significant differences between DKI cells versus control and single knock in cell lines using two separate anti-bodies ( Figure S8A ). 
However, we then examined phosphorylation of Pdk1's specific downstream p90RSK phosphorylation substrate, Ser221. To become fully activated Ser221 must be phosphorylated by Pdk1 after initial phosphorylation at separate serine and threonine residues by Erk (36) . Of note, the prior phosphorylation site we assayed by western blot was Ser380 which is a substrate of Erk. Similar to Ser380 phosphorylation, baseline levels of p90RSK Ser221 phosphorylation were elevated in DKI cells compared to controls (Figure S8B top panel) . However, when treated with a specific Pdk1 inhibitor in preclinical development, GSK2334470 (37), major differences in Ser221 p90RSK phosphorylation were observed. As seen in Figure S8B 
Our study and those of others suggested that mutant KRAS as a single allele requires a "second hit" to affect a phenotype, and this could be either increased copy number of mutant KRAS, or a second cooperating mutation e.g. mutation of a single PIK3CA allele. In concordance with this finding, initial analysis of archived colorectal cancer samples demonstrated that mutations in other oncogenes were more common in tumors with wild type KRAS or heterozygous mutant/wild type KRAS, compared to samples where only mutant KRAS was detected (Table S5) . Unfortunately, copy number data was not available for these samples.
Nonetheless, given these data and our DKI xenografts studies, we hypothesized that in cancers with a MIN phenotype, a more common mechanism may be to mutate a second oncogene given the nature of microsatellite instability, though certainly copy number changes can and do occur in MIN tumors and conversely, non-MIN tumors can also have mutations in both mutant KRAS and other cooperating oncogenes such as PIK3CA. However, we obtained a limited number of new colorectal cancer patient samples with KRAS mutations and PIK3CA mutations from four MIN cancers, as well as four non-MIN cancers with KRAS mutations but with wild type PIK3CA. We then tested their allelic ratios by standard sequencing of genomic DNA, as well as their gene copy number status of KRAS and PIK3CA using FISH. As seen in Figure 8 and Figure   S9 , MIN cancer cells had equivalent ratios of mutant to wild type KRAS and PIK3CA. Further analysis by FISH confirmed that these cancer cells had two copies each of KRAS and PIK3CA demonstrating that there were single alleles of mutant and wild type KRAS and PIK3CA. In 
DISCUSSION
The role of mutant KRAS towards carcinogenesis and maintenance of a cancerous phenotype has been extensively studied. Mouse models in particular have proven that a single mutant KRAS allele predisposes towards the development of certain tumors (38) . However, although these elegant models clearly demonstrate an increased susceptibility towards tumor development with a single mutant KRAS allele, most of these studies do not directly address the minimum genetic alterations that are required for mutant KRAS to elicit a transformed phenotype for establishing tumors. Jacks and colleagues demonstrated that increased mutant KRAS copy numbers can be found in tumors arising from mice with a single "latent" mutant KRAS allele (14) , suggesting that increased copy number may be one method that mutant KRAS imparts harbor single copies of mutant oncogenes, but importantly we acknowledge that increased copy number can be found in these tumors. Indeed, increased copy number may impart additional selective advantages during tumor evolution, drug resistance etc., such that cancers with mutations in both KRAS and PIK3CA with increased copy number of one or both mutant genes will be seen at some frequency. Similarly, non-MIN tumors may initially have increased copy number of a mutated oncogene such as KRAS, but develop additional mutations in other oncogenes during tumor evolution. Thus, the main focus of our study is that mutant KRAS as a single copy is insufficient to impart a phenotypic change, but that an additional alteration is required prior to any functional consequence. Further studies are ongoing to elucidate the consequences of increasing copy numbers of mutant KRAS and/or PIK3CA in these experimental systems and its relevance to tumor evolution and drug resistance.
Concordant with the data using MIN colorectal cancer cells, our study demonstrates that double knock in of mutant KRAS and mutant PIK3CA in the genetically stable human breast epithelial cell line MCF-10A, leads to tumor formation and importantly, tumors that arise from these DKI cells retain single copies of mutant KRAS and mutant PIK3CA. However, it is notable that additional mutations and pathway activation beyond mutant KRAS and PIK3CA is likely their model using double knock in of mutant KRAS G13D and mutant PIK3CA H1047R in hTERT immortalized human mammary epithelial cells shows lack of tumorigenicity in contrast to our results with all DKI clones. Although this could be due to differences in cellular background, this same group has also recently reported that the KRAS G13D mutation may be distinct from other KRAS mutations in terms of biologic phenotype; notably these mutations do not seem to predict for resistance to anti-EGFR antibody therapies (40) . Thus, the difference in GAPDH is shown as a loading control. 
